A multiplex thyroid-specific assay for quantification of circulating thyroid cell-free RNA in plasma of thyroid cancer patients

A multiplex thyroid-specific assay for quantification of circulating thyroid cell-free RNA in plasma of thyroid cancer patients

The standard of care for thyroid cancer management is thyroidectomy and adjuvant radioactive iodine (RAI). There is a paucity of clinical tool that quantifies residual thyroid volume reliably for precise adjuvant RAI dosing. Serum thyroglobulin (TG), tumour marker for thyroid cancer, takes 4 weeks f...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang, Samantha Peiling, Koh, Winston Lian Chye, Kong, Kiat Whye, Parameswaran, Rajeev, Loke, Kelvin Siu Hoong, Ngiam, Kee Yuan, Tan, Wee Boon, Loh, Thomas, Ng, David Chee Eng, Goh, Boon Cher, Ngeow, Joanne, Tai, E. Shyong
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2022
Subjects:
Science::Medicine
Thyroid-Specific Transcripts
Thyroglobulin Antibody Positivity
Online Access:https://hdl.handle.net/10356/154183
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:The standard of care for thyroid cancer management is thyroidectomy and adjuvant radioactive iodine (RAI). There is a paucity of clinical tool that quantifies residual thyroid volume reliably for precise adjuvant RAI dosing. Serum thyroglobulin (TG), tumour marker for thyroid cancer, takes 4 weeks for complete clearance due to its long half-life, and might be undetectable in 12% of structural disease patients. It detects recurrence with a sensitivity of 19-40%, mainly attributed to issue of TG antibody interference with TG immunometric assay. We hypothesise that the quantity of thyroid-specific cell-free RNA (cfRNA) is indicative of amount of thyroid tissues, and that during thyroid surgery, cfRNA levels decrease accordingly.

Similar Items